Although most patients with autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) respond to first-line immunotherapy, a subset is refractory to conventional treatments and experiences poor outcomes. This study evaluates the efficacy of tocilizuma... ...

请注册登录后继续浏览